AbbVie's Dividend Yield Is at Its Lowest Level Since 2018. Here's Why the Stock Is Still a Great Pick for Income Investors Anyway.

AbbVie’s dividend yield is around 2.6%, its lowest since early 2018, because its share price has risen faster than its dividend; the payout has increased nearly 333% since 2013, while shares have gained roughly 676%. The article points to Skyrizi and Rinvoq sales projected to exceed $29 billion combined in 2026 and says their Q2 2026 sales rose more than 24% year over year. Wall Street’s consensus 12-month price target implies about 5% upside, while cited analyst targets imply gains of 14% and nearly 18%; the article argues dividend growth and reliability continue to support the stock for income investors.

Analysis

ABBV’s lower yield is a valuation and entry-price issue, not evidence of dividend deterioration. For new income capital, the key question is whether future cash-flow growth can justify paying a materially higher price for each dollar of dividend; the article supplies no valuation, free-cash-flow coverage, or payout data to establish that. The cited ~5% consensus upside also suggests limited near-term room for execution misses, even if the longer-term product thesis holds.

The main second-order risk is that investors treat the post-Humira replacement story as de-risked. Sustained growth in Skyrizi and Rinvoq must be tested against competitive launches, pricing/reimbursement pressure, and the ability of the broader pipeline to replenish growth—not just headline sales targets. A slowdown would hit both expected cash-flow growth and the multiple supporting the reduced yield. AbbVie’s Apogee acquisition adds an execution and capital-allocation watch item; the supplied information does not establish its financial contribution. There is no direct read-through to Abbott Laboratories (ABT), which is a separate company.

Near term (days to weeks), the article is unlikely to create a durable catalyst by itself. Over 1–3 months, quarterly product sales, guidance, and cash conversion matter more than dividend-growth history. Over 6–18 months, the thesis depends on continued successor-drug growth and pipeline productivity. The contrarian point: dividend reliability can be real while the stock is still unattractive for fresh income buyers at a compressed yield. Reassess if product growth or free-cash-flow coverage weakens; those would challenge the thesis more directly than yield movement alone.

Key Decisions for Investors

• Existing ABBV holders: maintain positions sized for equity and product-execution risk, but do not add solely to capture the dividend. The yield has compressed, and the supplied consensus target implies modest near-term upside.
• New income allocation: wait for a better entry or for reported results to validate product growth and dividend coverage. Before adding, verify free-cash-flow conversion, payout coverage, and realized sales versus guidance; these data are absent here.
• Set an alert for a meaningful deceleration in Skyrizi/Rinvoq sales, a guidance reduction, or weakening cash-flow coverage. Any of these would undermine the growth-plus-dividend thesis and could pressure both earnings expectations and valuation.
• Treat APGE as a separate watch item, not a proxy for ABBV’s established cash flows: monitor disclosed integration costs, development progress, and any change in AbbVie’s capital-allocation outlook. No directional view on ABT follows from this article.